Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Earnings for Citius Pharmaceuticals, Inc. (CTXR)
Earnings in 2023 (TTM): $-31,966,912
According to Citius Pharmaceuticals, Inc.'s latest financial reports the company's current earnings (TTM) are $-31,966,912. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Citius Pharmaceuticals, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-31,966,912 | $-32,542,912 |
| 2022 | $-33,064,646 | $-33,640,646 |
| 2021 | $-23,054,434 | $-23,125,190 |
| 2020 | $-17,548,085 | $-17,673,965 |
| 2019 | $-15,562,144 | $-15,578,587 |
| 2018 | $-12,536,638 | $-12,536,638 |
| 2017 | $-10,384,953 | $-10,384,953 |
| 2016 | $-8,295,698 | $-8,295,698 |
| 2015 | $-2,902,268 | $-2,902,268 |
| 2014 | $-1,272,141 | $-1,272,141 |
| 2013 | $-31,369 | $-31,369 |
| 2012 | $-22,006 | $-22,006 |
| 2011 | $-26,341 | $-26,341 |